Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board Appointment

27 Mar 2019 07:00

RNS Number : 0991U
Frontier IP Group plc
27 March 2019
 

27 March 2019

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Board Appointment

 

Frontier IP, a specialist in commercialising university intellectual property, is pleased to announce that Matthew White has joined the Board of Frontier IP with immediate effect. Matthew was appointed to the senior management team of Frontier IP as Director of Commercialisation on 17 September 2018 and will continue in this role.

 

Matthew has over 23 years' experience in technology, product and service innovation, business development and marketing. In his previous role he was Head of Innovation at AB Sugar, part of FTSE 100 group AB Foods. He also has extensive experience working with university partners. Before joining AB Sugar, Matthew was Director of Consumer Products for international technology consulting and product development business, Sagentia Limited, working across a wide range of sectors. He started his career at Neotronics Scientific, one of the first companies to commercialise electronic odour sensing. He has a Natural Sciences degree majoring in Chemistry from the University of Cambridge.

 

Neil Crabb, CEO of Frontier IP Group plc, said: "Matt has proved a great addition to our team since joining us last year with his expertise helping to drive innovation for a FTSE 100 group and, before then, working for a leading Cambridge consultancy.

 

His experience is central to what we do at Frontier IP in supporting our portfolio companies through early industry engagement to ensure their technology works, can be scaled up and meets the needs and demands of customers in the real world. His well-deserved appointment to the board reflects the invaluable work he has undertaken to date."

 

 

Regulatory Disclosures

 

In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, Matthew Charles White, aged 45, does not hold any current directorships or partnerships, nor has he held any directorships or partnerships within the last five years.

 

Matthew White does not currently hold any ordinary shares in Frontier IP. He holds 136,000 options over ordinary shares and further details on the options granted to Matthew White were announced by the Company on 15 November 2018.

 

There is no other information required to be disclosed under the AIM Rules for Companies in relation to the appointment of Matthew White to the board of Frontier IP.

 

ENQUIRIES

 

Frontier IP Group Plc

T: 0131 240 1251

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications & Investor Relations

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas

 

Nicholas Chambers

 

 

ABOUT FRONTIER IP: www.frontierip.co.uk

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOALFFSLVTIRFIA
Date   Source Headline
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update
28th Apr 20217:00 amRNSExscientia Series D funding led by SoftBank
20th Apr 20217:00 amRNSHolding(s) in Company
24th Mar 20217:00 amRNSUnaudited Half Year Results
19th Mar 20217:00 amRNSFieldwork Robotics raises £675,000
18th Mar 20217:00 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSAlusid - appoints David Taylor CBE to the Board
12th Mar 202112:27 pmRNSHolding(s) in Company
12th Mar 20217:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSinSignals Neurotech receives EUR100,000 investment
9th Mar 20217:00 amRNSUN awards $250,000 grant to AquaInSilico
8th Mar 20219:05 amRNSSecond Price Monitoring Extn
8th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:30 amRNSExscientia completes $100 million Series C funding
22nd Feb 20217:00 amRNSPulsiv Solar raises £890,000
16th Feb 20217:00 amRNSPublication of newsletter
16th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSFrontier IP supports breakthrough technology
18th Jan 20217:00 amRNSHolding(s) in Company
15th Jan 20217:00 amRNSAppointment of Darren Winter
11th Jan 20217:00 amRNSPortfolio news – Elute Intelligence raises £250k
29th Dec 20201:44 pmRNSHolding(s) in Company
17th Dec 202012:30 pmRNSResult of AGM
1st Dec 20207:00 amRNSCambridge Raman participates in EUR 5m project
20th Nov 20207:00 amRNSPosting of Annual Report and Notice of AGM
16th Nov 20207:00 amRNSFrontier IP: recording of annual results webcast
16th Nov 20207:00 amRNSPortfolio news – Fieldwork SIF grant
13th Nov 20202:03 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.